NASDAQ:ADXSAdvaxis Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Advaxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.57 -0.01 (-1.74 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.57Now: $0.57▼$0.6150-Day Range$0.53MA: $0.59▼$0.6652-Week Range$0.21Now: $0.57▼$1.48Volume23,682 shsAverage Volume896,250 shsMarket Capitalization$35.13 millionP/E RatioN/ADividend YieldN/ABeta3.53 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; MedImmune/AstraZeneca; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Advaxis. Previous Next 2.4 Community Rank Outperform VotesAdvaxis has received 365 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdvaxis has received 407 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdvaxis has received 52.72% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote “Outperform” if you believe ADXS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdvaxis does not currently pay a dividend.Dividend GrowthAdvaxis does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Advaxis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.26% of the stock of Advaxis is held by insiders.Percentage Held by InstitutionsOnly 11.24% of the stock of Advaxis is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Advaxis is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Advaxis is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdvaxis has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADXS Previous Symbol CUSIPN/A CIK1100397 Webwww.advaxis.com Phone609-452-9813Debt Debt-to-Equity Ratio0.16 Current Ratio7.52 Quick Ratio7.52Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20.88 million Price / Sales1.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book0.25Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-16,610,000.00 Net Margins-13,144.62% Return on Equity-82.46% Return on Assets-69.06%Miscellaneous Employees58 Outstanding Shares61,610,000Market Cap$35.13 million Next Earnings Date9/14/2020 (Estimated) OptionableOptionable $0.57 -0.01 (-1.74 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ADXS News and Ratings via Email Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Advaxis (NASDAQ:ADXS) Frequently Asked Questions How has Advaxis' stock been impacted by COVID-19 (Coronavirus)? Advaxis' stock was trading at $0.6666 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADXS shares have decreased by 14.5% and is now trading at $0.5702. View which stocks have been most impacted by Coronavirus. When is Advaxis' next earnings date? Advaxis is scheduled to release its next quarterly earnings announcement on Monday, September 14th 2020. View our earnings forecast for Advaxis. How were Advaxis' earnings last quarter? Advaxis, Inc. (NASDAQ:ADXS) issued its quarterly earnings data on Thursday, June, 11th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.05. The biotechnology company earned $0.25 million during the quarter. Advaxis had a negative return on equity of 82.46% and a negative net margin of 13,144.62%. View Advaxis' earnings history. Has Advaxis been receiving favorable news coverage? Media headlines about ADXS stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Advaxis earned a daily sentiment score of 1.6 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Advaxis. Who are some of Advaxis' key competitors? Some companies that are related to Advaxis include CELYAD SA/ADR (CYAD), OASMIA PHARMACE/ADR (OASM), Kindred Biosciences (KIN), KITOV PHARMA LT/S (KTOV), Inflarx (IFRX), Checkpoint Therapeutics (CKPT), Obseva (OBSV), BIOFRONTERA AG/ADR (BFRA), Sierra Oncology (SRRA), Evelo Biosciences (EVLO), PhaseBio Pharmaceuticals (PHAS), SUMMIT THERAPEU/S (SMMT), Rockwell Medical (RMTI), Corvus Pharmaceuticals (CRVS) and Axovant Gene Therapies (AXGT). View all competitors. What other stocks do shareholders of Advaxis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Merck & Co., Inc. (MRK), Vistagen Therapeutics (VTGN), Anavex Life Sciences (AVXL), Celgene (CELG), Highpower International (HPJ), BIOLINERX LTD/S (BLRX), Novavax (NVAX) and Opko Health (OPK). Who are Advaxis' key executives? Advaxis' management team includes the following people: Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)Mr. Anthony A. Lombardo, Exec. Officer (Age 70)Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58) What is Advaxis' stock symbol? Advaxis trades on the NASDAQ under the ticker symbol "ADXS." How do I buy shares of Advaxis? Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Advaxis' stock price today? One share of ADXS stock can currently be purchased for approximately $0.57. How big of a company is Advaxis? Advaxis has a market capitalization of $35.13 million and generates $20.88 million in revenue each year. Advaxis employs 58 workers across the globe. What is Advaxis' official website? The official website for Advaxis is www.advaxis.com. How can I contact Advaxis? Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected] This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
